CYP2D6 and CYP1A1 mutations in the Turkish population

Cell Biochemistry and Function

Volumn 23, Issue 2, 2005, Pages 133-135

  Aydin, Muge ^a   Hatirnaz, Ozden ^a   Erensoy, Nevin ^a   Ozbek, Ugur ^a,b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Genetics Department   (Turkey)

Author keywords

CYP1A1 polymorphism; CYP2D6; Turkish population

Indexed keywords

CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; DRUG; GLUTATHIONE TRANSFERASE; MUTANT PROTEIN;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; DRUG METABOLISM; DRUG RESPONSE; ENZYME SUBSTRATE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; TURKEY (REPUBLIC); XENOBIOTIC METABOLISM;

ADOLESCENT; ADULT; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TURKEY;

EID: 14944357375     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbf.1222     Document Type: Article

References (11)

1. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998; 19: 1329-1332.
2. Ryder W. Metabolic polymorphisms and susceptibility to cancer. In Cytochrome p450 CYP2D6, vol. 148, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzik J, Bofetta P (eds). IARC Scientific Publications: Lyon, 1999; 202-229.
3. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996; 88: 496-509.
4. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999; 93: 1496-1501.
5. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999; 436: 227-261.
6. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogencsis 1999; 20: 1225-1229.
7. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
8. Hakkola J, Raunio H, Purkunen R, et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 2001; 80: 193-201.
9. Roddam PL, Rollinson S, Kane E, et al. Poor metabolizers at the Cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 2000; 10: 605-615.
10. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66: 185-192.
11. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I. High frequency of CYP1A1 mutations in aTurkish population. Arch Toxicol 1998; 72: 215-218.